PALI - Palisade Bio, Inc. Annual Revenue Growth (Last Twelve Months)

Brandmark of palisadebio.com (PALI)

Risks for Palisade Bio, Inc. (PALI) stem from a dependence on a single project and a shortage of research funding. However, strong pricing power within the gastrointestinal protease inhibitor niche supports the share price. The current balance sheet relies on external loans due to liquidity burn. This chart of trailing 12-month sales volume dynamics versus the prior year reflects a business maturity phase, where the metric has plateaued at 0.00.

Sales Growth YoY (TTM): Palisade Bio (PALI) for 02/11/2024 - 11/17/2026

Palisade Bio Inc. (PALI) - metric breakdowns and financial figures

- stock price and consensus target price:
Fundamental company valuation:Palisade Bio
Flagship merchandise of Palisade Bio

This indicator reflects daily revenue dynamics over the last 12 months, capturing the deviation of current sales volumes from the same period last year to identify operational cycles. An analysis of the LTM sales growth YoY metric with a value of 0.00 confirms that Palisade Bio, Inc. lacks commercial products, as its viability in the gastroenterology sector currently relies entirely on external funding.